Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid LeukemiaAdvanced Myelodysplastic Syndromes
- Interventions
- Drug: Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT00629798
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2008-02-04
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 154
- Registration Number
- NCT00606723
- Locations
- 🇦🇹
Graz University Hospital, Graz, Austria
🇦🇹Innsbruck University Hospital, Innsbruck, Austria
🇦🇹St. Anna Children Hospital, Wien, Austria
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
- Conditions
- Leukemia, MyeloidLeukemiaAcute Myeloid Leukemia (AML)
- Interventions
- Procedure: Allogeneic HSCTDrug: Best standard careDrug: Anti-thymocyte globulin (ATG)Radiation: Total lymphoid irradiation (TLI)
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 58
- Registration Number
- NCT00568633
- Locations
- 🇺🇸
Kaiser Permanente Northern California, Hayward, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Univeristy of California Davis Medical Center, Sacramento, California, United States
Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2007-11-29
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Aptose Biosciences Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00565058
- Locations
- 🇺🇸
San Francisco Veterans Affairs Medical Center, San Francisco, California, United States
🇺🇸UCSF Medical Center, San Francisco, California, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
- Conditions
- Leukemia
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 15
- Registration Number
- NCT00548847
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)
- Conditions
- Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 38
- Registration Number
- NCT00531232
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
🇺🇸Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)
- Conditions
- Myelodysplastic SyndromeLeukemia
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 191
- Registration Number
- NCT00525746
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
- Conditions
- Acute Myeloid Leukemia (AML)Chronic Myeloid Leukemia (CML)Myelodysplastic Syndrome (MDS)
- Interventions
- Biological: Montanide adjuvant
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2021-07-12
- Target Recruit Count
- 10
- Registration Number
- NCT00488592
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
- Conditions
- Myelodysplastic SyndromesAcute Myeloid LeukemiaLeukemia
- Interventions
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00480987
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
- Conditions
- Chronic Myeloid Leukemia (CML)Myelodysplastic SyndromeAcute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2014-07-08
- Target Recruit Count
- 4
- Registration Number
- NCT00433745
- Locations
- 🇺🇸
National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, United States